AG-QUETIAPINE FUMARATE TABLET (IMMEDIATE RELEASE)
Krajina: Kanada
Jazyk: angličtina
Zdroj: Health Canada
Súhrn charakteristických
(SPC)
11-06-2021
Niektoré dokumenty týkajúce sa tohto produktu nie sú momentálne k dispozícii, môžete poslať požiadavku na náš zákaznícky servis a my vás upozorníme hneď, ako ich dokážeme získať.
Poslať žiadosť.
Poslať žiadosť.
Aktívna zložka:
QUETIAPINE (QUETIAPINE FUMARATE)
Dostupné z:
ANGITA PHARMA INC.
ATC kód:
N05AH04
INN (Medzinárodný Name):
QUETIAPINE
Dávkovanie:
25MG
Forma lieku:
TABLET (IMMEDIATE RELEASE)
Zloženie:
QUETIAPINE (QUETIAPINE FUMARATE) 25MG
Spôsob podávania:
ORAL
Počet v balení:
15G/50G
Typ predpisu:
Prescription
Terapeutické oblasti:
ATYPICAL ANTIPSYCHOTICS
Prehľad produktov:
Active ingredient group (AIG) number: 0131858001; AHFS:
Stav Autorizácia:
APPROVED
Dátum Autorizácia:
2021-06-14
Súhrn charakteristických
Page 1 of 59
PRODUCT MONOGRAPH
PR
AG-QUETIAPINE FUMARATE
Quetiapine Tablets USP
25 mg, 100 mg, 200 mg and 300 mg
quetiapine (as quetiapine fumarate)
Antipsychotic Agent
_ANGITA PHARMA INC. _
_DATE OF REVISION:_
1310 rue Nobel
June 11, 2021
Boucherville, Québec
J4B 5H3
Submission Control No.: 252148
Page 2 of 59
TABLE OF CONTENTS
PRODUCT MONOGRAPH
....................................................................................................
1
PART I: HEALTH PROFESSIONAL INFORMATION
......................................................... 3
SUMMARY PRODUCT INFORMATION
......................................................................
3
INDICATIONS AND CLINICAL USE
...........................................................................
3
CONTRAINDICATIONS
................................................................................................
4
WARNINGS AND PRECAUTIONS
...............................................................................
4
ADVERSE REACTIONS
...............................................................................................
15
DRUG INTERACTIONS
...............................................................................................
31
DOSAGE AND ADMINISTRATION
...........................................................................
33
OVERDOSAGE
.............................................................................................................
35
ACTION AND CLINICAL PHARMACOLOGY
.......................................................... 36
STORAGE AND STABILITY
.......................................................................................
38
DOSAGE FORMS, COMPOSITION AND PACKAGING
........................................... 38
PART II: SCIENTIFIC INFORMATION
.............................................................................
39
PHARMACEUTICAL INFORMATION
.......................................................................
39
CLINICAL TRIALS
..........................................................................
Prečítajte si celý dokument
